Novo Nordisk Breakfast Symposium — ASN Events
7:00AM - 8:30AM
103

Patient and HCP attitudes and behaviours towards insulin therapy in Australia (GAPP2), and latest news on Novo Nordisk injectable therapies
An international cross-sectional survey (GAPP2), with a cohort in Australia, was conducted to increase the understanding of basal insulin-taking with an aim to investigate the frequency and impact of basal insulin dosing irregularities and hypoglycaemia in type 2 diabetes. The survey was conducted with both patients and physicians, and thus the difference in perceptions between the two groups was explored. The survey found a proportion of patients dosed their basal insulin irregularly which may warrant more frequent discussion with prescribers to address the behaviours and reasons behind this.

Novo Nordisk is constantly exploring opportunities to make their products more widely available to a larger number of patient groups. An update to the audience will be provided on the latest developments of Novo Nordisk’s injectable portfolio.

@ADSADEA